P0108 Overexpression of DPP4 is a poor prognostic factor for patients with urothelial carcinoma of the upper urinary tract and urinary bladder

2014 ◽  
Vol 50 ◽  
pp. e39
Author(s):  
P-I. Liang ◽  
W-J. Wu ◽  
C-N. Huang ◽  
C-C. Li ◽  
H-L. Ke ◽  
...  





2017 ◽  
Vol 15 (4) ◽  
pp. e543-e550 ◽  
Author(s):  
Takashi Yoshida ◽  
Hidefumi Kinoshita ◽  
Seiji Shimada ◽  
Motohiko Sugi ◽  
Tadashi Matsuda






2019 ◽  
Vol 8 (8) ◽  
pp. 1190 ◽  
Author(s):  
Igor Duquesne ◽  
Idir Ouzaid ◽  
Yohann Loriot ◽  
Marco Moschini ◽  
Evanguelos Xylinas

Background: The role of lymphonodal dissection during surgery for a tumor of the urinary tract remains controversial. Objective: To analyze anatomical bases of lymphonodal dissection in tumors of the upper urinary tract and analyze its impact on survival, recurrence, and staging. Acquisition of data: A web-based search for scientific articles using Medline/Pubmed was carried out to identify and analyze articles on the practice and the role of lymphonodal dissection in this indication. Data Synthesis: The lymphatic drainage of the upper urinary tract has rarely been studied and is poorly understood. The lymphonodal metastatic extension is the most common extension in upper urinary tract urothelial carcinoma. Lymphnode invasion is a clear independent poor prognostic factor. Therefore, it seems legitimate to offer an extended lymphonodal dissection to patients undergoing surgery to cure these tumors. When lymphnodes dissection respects clear anatomical principles based on the location of the primary tumor and its extension, it improves both survival and recurrence rates. This result could be secondary to the treatment of subclinical metastatic disease. Conclusion: An extended lymphadenectomy during surgery for upper urinary tract urothelial carcinoma following strict anatomical pattern improves staging with a highly probable therapeutic benefit.



2021 ◽  
Author(s):  
Chien-Cheng Lai ◽  
Tzu-Ju Chen ◽  
Ti-Chun Chan ◽  
Wan-Shan Li ◽  
Hong-Lin He

Background: Bioinformatic analysis has revealed that OXR1 is significantly downregulated in muscle-invasive bladder cancer. Patients & methods: The expression of OXR1 in patients with urothelial carcinoma was evaluated by immunohistochemistry, including 340 cases with urothelial carcinoma in the upper urinary tract and 295 in the urinary bladder. Results: Low expression of OXR1 was significantly correlated with adverse pathological parameters including high primary tumor (pT) stage, high node stage, high histological grade, high mitotic activity and increased vascular or perineural invasion (all p < 0.05). Low expression of OXR1 independently predicted worse metastasis-free survival (p = 0.033) in urothelial carcinoma of the upper urinary tract and worse disease-specific survival (p = 0.022) and metastasis-free survival (p < 0.001) in urothelial carcinoma of the urinary bladder. Conclusion: Low expression of OXR1 is an adverse prognostic factor in urothelial carcinoma.



Renal Failure ◽  
2016 ◽  
Vol 38 (5) ◽  
pp. 663-670 ◽  
Author(s):  
Po-Jen Hsiao ◽  
Po-Fan Hsieh ◽  
Chao-Hsiang Chang ◽  
Hsi-Chin Wu ◽  
Chi-Rei Yang ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document